Clinical Trial Update: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

An ongoing phase 1/2 clinical trial is evaluating the combination of nivolumab and ruxolitinib for relapsed or refractory classical Hodgkin lymphoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Veronika Bachanova | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING